Drug Profile

YH 29407

Alternative Names: YH-29407

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Yuhan
Class Antineoplastics
Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

No development reported Solid tumours

Most Recent Events

28 May 2025 No recent reports of development identified for preclinical development in Solid-tumours in South Korea (Intratumoural)
08 Apr 2022 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
02 Jun 2021 YH 29407 is available for licensing as of 02 Jun 2021. http://eng.yuhan.co.kr/RnD/Vision/Collaboration/

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com